China’s Volume-Based Procurement Policy a Seismic Shift for Orthopedic Players

Orthopedics recently got its first taste of price reductions from China’s national volume-based procurement policy for hip and knee replacement products. The procurement policy previously brought the price of coronary drug-eluding stents down 96% from the headline price of Medtronic’s Resolute Integrity product. In mid-September 2021, Chinese...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us